LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/New Pain Killer for Joint Replacement
Large Joints and Extremities

New Pain Killer for Joint Replacement

January 27, 2015 1 min read Premium comments

Advertisement

New Pain Killer for Joint Replacement
Source: Wikimedia Commons and Tomas Arad
Secondary

More than half of all adults in the U.S. who are diagnosed with knee osteoarthritis will undergo knee replacement surgery, according to a Workers Compensation estimate. While the surgical techniques have continued to improve, pain control has not.

A study at Henry Ford Hospital, Detroit, Michigan, found that if doctors injected a newer, long-acting medicine called liposomal bupivacaine into the tissue surrounding the knee during surgery patients felt dramatically less pain. Jason Davis, M.D., a Henry Ford West Bloomfield Hospital joint replacement surgeon and the study’s senior author said, “Patients had pain relief for up to two days after surgery and better knee function compared with the traditional method.”

In the Henry Ford study, researchers evaluated 216 patients for pain control during the first two days after joint replacement surgery. Researchers gave half of the patients the traditional pain control which involves a continuous femoral nerve blockade. Doctors injected numbing medicine into the groin area which blunts the main nerve down the front of the knee. This caused some patients leg weakness. “Pain control came at the price of weakness and made patients somewhat tentative when walking during their hospital stay, ” Davis said.

Researchers gave the other half of the patient group an injection of liposomal bupivacaine at the site of the surgery. Davis reports that many of these patients were able to walk comfortably within hours after surgery. He observed that, “function-wise, it was a lot easier for patients to move around more confidently. This option is a promising, viable one for our patients, ” he concluded.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy